SG10201407935YA - Humanized anti-il-10 antibodies for the treatment of systemic lupus erythematosus (sle) - Google Patents

Humanized anti-il-10 antibodies for the treatment of systemic lupus erythematosus (sle)

Info

Publication number
SG10201407935YA
SG10201407935YA SG10201407935YA SG10201407935YA SG10201407935YA SG 10201407935Y A SG10201407935Y A SG 10201407935YA SG 10201407935Y A SG10201407935Y A SG 10201407935YA SG 10201407935Y A SG10201407935Y A SG 10201407935YA SG 10201407935Y A SG10201407935Y A SG 10201407935YA
Authority
SG
Singapore
Prior art keywords
sle
antibodies
treatment
lupus erythematosus
systemic lupus
Prior art date
Application number
SG10201407935YA
Inventor
Frank Osterroth
Christoph Uherek
Christoph Bruecher
Peter Röttgen
Benjamin Daelken
André Engling
Chantal Zuber
Niklas Czeloth
Original Assignee
Biotest Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0920942A external-priority patent/GB0920942D0/en
Priority claimed from GB0920933A external-priority patent/GB0920933D0/en
Priority claimed from GB0920940A external-priority patent/GB0920940D0/en
Application filed by Biotest Ag filed Critical Biotest Ag
Publication of SG10201407935YA publication Critical patent/SG10201407935YA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G01N33/6869—Interleukin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2299/00—Coordinates from 3D structures of peptides, e.g. proteins or enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Abstract

49 HUMANIZED ANTI-IL-10 ANTIBODIES FOR THE TREATMENT OF SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) Abstract: Provided is a humanized or chimeric antibody or fragment thereof capable of binding to interleukin-10 (IL- 10), wherein said antibody or fragment thereof: (i) binds to the same region of IL-10 as the IL-10 receptor a (IL-IlORa) and is not capable of binding IL-10 when the IL-10 is bound to the IL- 10 receptor; and (ii) binds to IL-10 in homodimeric form by binding a discontinuous epitope comprising residues of both monomers. Further provided are related products and methods involving the use of the antibodyor fragment thereof. Nosuitabledrawing
SG10201407935YA 2009-11-30 2010-11-30 Humanized anti-il-10 antibodies for the treatment of systemic lupus erythematosus (sle) SG10201407935YA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0920942A GB0920942D0 (en) 2009-11-30 2009-11-30 Agent for treating disease
GB0920933A GB0920933D0 (en) 2009-11-30 2009-11-30 Agent for treating disease
GB0920940A GB0920940D0 (en) 2009-11-30 2009-11-30 Agent for treating disease

Publications (1)

Publication Number Publication Date
SG10201407935YA true SG10201407935YA (en) 2015-01-29

Family

ID=43798505

Family Applications (2)

Application Number Title Priority Date Filing Date
SG10201407935YA SG10201407935YA (en) 2009-11-30 2010-11-30 Humanized anti-il-10 antibodies for the treatment of systemic lupus erythematosus (sle)
SG10201407936XA SG10201407936XA (en) 2009-11-30 2010-11-30 Humanized anti-il-10 antibodies for the treatment of systemic lupus erythematosus (sle)

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG10201407936XA SG10201407936XA (en) 2009-11-30 2010-11-30 Humanized anti-il-10 antibodies for the treatment of systemic lupus erythematosus (sle)

Country Status (17)

Country Link
US (4) US8956607B2 (en)
EP (2) EP2470209B1 (en)
JP (2) JP2013511994A (en)
KR (2) KR101802260B1 (en)
CN (2) CN102811736B (en)
AU (2) AU2010323036B2 (en)
BR (2) BR112012012912A2 (en)
CA (2) CA2782004A1 (en)
CO (1) CO6561779A2 (en)
CR (2) CR20120359A (en)
IL (2) IL219954A (en)
MX (2) MX350206B (en)
NZ (2) NZ600899A (en)
RU (2) RU2581812C2 (en)
SG (2) SG10201407935YA (en)
WO (2) WO2011064398A1 (en)
ZA (1) ZA201204843B (en)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101802260B1 (en) 2009-11-30 2017-11-28 바이오테스트 아게 Humanized anti-il-10 antibodies for the treatment of systemic lupus erythematosus (sle)
EP2986306A4 (en) 2013-04-18 2016-12-07 Armo Biosciences Inc Methods of using interleukin-10 for treating diseases and disorders
WO2014176373A2 (en) * 2013-04-24 2014-10-30 Armo Biosciences, Inc. Interleukin-10 compositions and uses thereof
EP3434277A1 (en) 2013-06-17 2019-01-30 Armo Biosciences, Inc. Method for assessing protein identity and stability
AU2014311432A1 (en) 2013-08-30 2016-03-03 Armo Biosciences, Inc. Methods of using interleukin-10 for treating diseases and disorders
KR20160079114A (en) 2013-11-11 2016-07-05 아르모 바이오사이언시스 인코포레이티드 Methods of using interleukin-10 for treating diseases and disorders
AU2015213735A1 (en) * 2014-02-10 2016-08-04 Merck Sharp & Dohme Corp. Antibodies that bind to human Tau and assay for quantifying human Tau using the antibodies
US10725030B2 (en) 2014-11-28 2020-07-28 Ge Healthcare Bio-Sciences Ab Method for determining analyte-ligand binding on a sensor surface
WO2016096896A1 (en) * 2014-12-15 2016-06-23 Morphosys Ag Antibodies for il-17c
WO2016126615A1 (en) 2015-02-03 2016-08-11 Armo Biosciences, Inc. Methods of using interleukin-10 for treating diseases and disorders
KR20180020141A (en) 2015-05-28 2018-02-27 아르모 바이오사이언시스 인코포레이티드 PEGylated interleukin-10 for cancer treatment
US10398761B2 (en) 2015-08-25 2019-09-03 Armo Biosciences, Inc. Methods of using combinations of PEG-IL-10 and IL-15 for treating cancers
JP6794448B2 (en) 2015-12-04 2020-12-02 ノバルティス アーゲー Antibody Cytokine Graft Composition and Usage for Immunomodulation
WO2019072566A1 (en) 2017-10-10 2019-04-18 Biotest Ag Combination of anti-il10 and anti-pd1 antibodies in cancer treatment
AR114112A1 (en) * 2018-02-15 2020-07-22 Seattle Genetics Inc GLIPICAN 3 ANTIBODIES AND CONJUGATES THEREOF
EP3892280A3 (en) 2020-04-09 2022-01-12 Children's Hospital Medical Center Sars-cov-2 infection biomarkers and uses thereof
WO2021206766A1 (en) 2020-04-09 2021-10-14 Children's Hospital Medical Center Sars-cov-2 infection biomarkers and uses thereof
US11324750B2 (en) 2020-04-09 2022-05-10 Children's Hospital Medical Center Compositions and methods for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection
CA3200884A1 (en) 2020-11-18 2022-05-27 Astrazeneca Ab Steroid sparing
IL305969A (en) * 2021-03-23 2023-11-01 Organogenesis Inc Methods kits and compositions for characterizing an anti-inflammatory response of a product

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
MY108267A (en) 1991-01-16 1996-09-30 Schering Corp Use of interleukin-10 in adoptive immunotherapy of cancer
EP0590058B1 (en) * 1991-06-14 2003-11-26 Genentech, Inc. HUMANIZED Heregulin ANTIBODy
PT600970E (en) 1991-08-06 2000-05-31 Schering Corp USE OF INTERLEUCIN-10 ANALOGUES OR ANTAGONISTS TO TREAT ENDOTOXIN-INDUCED TOXICITY OR SUPERANTIGENS
US5833976A (en) 1991-08-06 1998-11-10 Schering Corporation Use of interleukin-10 (IL-10) to treat endotoxin- or superantigen-induced toxicity
DE4425115A1 (en) 1994-07-15 1996-01-18 Boehringer Mannheim Gmbh Method for modifying the stability of antibodies
DE19529026C2 (en) 1995-07-28 1997-06-19 Robert Sabat Monoclonal antibodies against human interleukin-10
PT1572744E (en) 2002-12-16 2010-09-07 Genentech Inc Immunoglobulin variants and uses thereof
WO2005047324A2 (en) 2003-11-10 2005-05-26 Schering Corp Interleukin-10 antibodies
KR101667944B1 (en) * 2007-08-29 2016-10-20 사노피 Humanized anti-CXCR5 antibodies, derivatives thereof and their uses
KR101802260B1 (en) * 2009-11-30 2017-11-28 바이오테스트 아게 Humanized anti-il-10 antibodies for the treatment of systemic lupus erythematosus (sle)

Also Published As

Publication number Publication date
WO2011064399A1 (en) 2011-06-03
BR112012012912A2 (en) 2016-10-25
IL219955A (en) 2016-08-31
MX2012006197A (en) 2012-06-19
CN102811736B (en) 2016-01-20
MX2012006198A (en) 2012-06-19
NZ600899A (en) 2014-09-26
IL219955A0 (en) 2012-07-31
KR20120103664A (en) 2012-09-19
CN102811736A (en) 2012-12-05
CN102711829B (en) 2016-03-16
WO2011064398A1 (en) 2011-06-03
RU2587622C2 (en) 2016-06-20
AU2010323037A1 (en) 2012-07-19
CR20120358A (en) 2013-01-23
US8956607B2 (en) 2015-02-17
AU2010323036B2 (en) 2015-01-29
JP2013511995A (en) 2013-04-11
JP2013511994A (en) 2013-04-11
KR101802260B1 (en) 2017-11-28
US20150218270A1 (en) 2015-08-06
US20150064179A1 (en) 2015-03-05
RU2581812C2 (en) 2016-04-20
CN102711829A (en) 2012-10-03
CA2782007C (en) 2018-07-24
AU2010323036A1 (en) 2012-07-19
EP2470209B1 (en) 2020-01-01
US20120321618A1 (en) 2012-12-20
IL219954A (en) 2016-10-31
RU2012127380A (en) 2014-01-10
KR101802261B1 (en) 2017-11-28
US20120321617A1 (en) 2012-12-20
ZA201204843B (en) 2020-02-26
CR20120359A (en) 2013-01-25
AU2010323037B2 (en) 2015-01-29
EP2470209A1 (en) 2012-07-04
NZ600894A (en) 2014-09-26
SG10201407936XA (en) 2015-01-29
MX350206B (en) 2017-08-28
CA2782004A1 (en) 2011-06-03
CO6561779A2 (en) 2012-11-15
US9540436B2 (en) 2017-01-10
EP2470208A1 (en) 2012-07-04
RU2012127381A (en) 2014-01-10
BR112012012917A2 (en) 2016-10-25
US8852871B2 (en) 2014-10-07
MX343228B (en) 2016-10-26
US9605066B2 (en) 2017-03-28
IL219954A0 (en) 2012-07-31
KR20120115289A (en) 2012-10-17
JP6005519B2 (en) 2016-10-12
CA2782007A1 (en) 2011-06-03

Similar Documents

Publication Publication Date Title
SG10201407935YA (en) Humanized anti-il-10 antibodies for the treatment of systemic lupus erythematosus (sle)
WO2013188693A8 (en) Antigen binding constructs to cd3
TN2013000417A1 (en) Antibody polypeptides that antagonize cd40
NZ607969A (en) Cd33 binding agents
CA2849765C (en) Hybrid constant regions
WO2010017103A3 (en) Fully human anti-human nkg2d monoclonal antibodies
IL209277A (en) Antibodies and antigen-binding fragments thereof that bind interleukin 6 receptor and the complex of interleukin 6 and interleukin 6 receptor
IL198379A (en) Humanized antibodies and antibody fragments that specifically bind sphingosine-1-phosphate, nucleic acids encoding the same and compositions and methods for use thereof to treat disease
NZ610267A (en) A monoclonal antibody framework binding interface for meditopes, meditope delivery systems and methods for their use
MX357231B (en) Antibody polypeptides that antagonize cd40l.
EA030777B9 (en) Anti-alpha synuclein binding molecules
PH12014502527A1 (en) St2 antigen binding proteins
WO2009052400A8 (en) Antibodies that bind to mammalian ngal and uses thereof
MX2013013832A (en) Fc RECEPTOR BINDING PROTEINS.
SG10201804513WA (en) Antibodies Against Fcrn And Use Thereof
CR20120312A (en) NEUTRALIZING ANTIBODIES AGAINST THE PROLACTIN RECEPTOR AND THERAPEUTIC USE
WO2010081679A3 (en) Antibodies against human epo receptor
MX341309B (en) Anti-il-23 heterodimer specific antibodies.
MX2010006767A (en) Hepatitis c virus antibodies.
NZ629553A (en) Anti-big-endothelin-1 (big-et-1) antibodies and uses thereof
WO2011092593A3 (en) Hiv-1 neutralizing antibodies and uses thereof
MY166152A (en) Anti-human xcr1 antibodies
MX343117B (en) Anti-human epo receptor antibodies and methods of use.
AP4074A (en) Monoclonal antibody directed against the p17 protein of hiv, capable of neutralising the binding of p17 to the p17 receptor (p17r)
WO2011050104A3 (en) Methods of using anti-cd3 antibodies to prevent weight gain